Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma

World News: . []

CAMBRIDGE Mass and SAN CARLOS Calif Dec 06 2018 GLOBE NEWSWIRE) -- Neon Therapeutics Inc Nasdaq NTGN a clinical-stage immuno-oncology company developing neoantigen-based therapeutics and Apexigen, Inc a clinical-stage biopharmaceu tical c...

More news and information about Neon Therapeutics, Inc.

Published By:

Globe Newswire: 12:00 GMT Thursday 6th December 2018

Published: .

Search for other references to "neon" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us